Executive Summary

Systematic reviews and evidence syntheses remain painfully manual: teams routinely screen thousands of PDFs, extract structured outcomes, and assemble auditable datasets by hand, consuming months of labor and significant budget. This burden falls on an estimated 600,000 research teams across universities, pharma R&D, NGOs and clinical review units and supports a roughly $3.6B market at an average contract value near $6,000 per team. You could build an AI-powered PDF screening and data-extraction platform that pairs LLM/document-AI models with human-in-the-loop workflows: automated deduplication, title/abstract and full-text triage, PICO/outcome and table extraction, risk-of-bias suggestions, PRISMA flow generation, and integrations with common reference managers and review platforms. Critical product requirements are auditable provenance for every extracted datapoint, per-item confidence scores with easy reviewer overrides, and enterprise features (SAML, on‑prem or VPC deployment) for pharma and regulated customers. Operationalizing this means validating models on labeled corpora and reporting measurable accuracy—e.g., targeting screening recall >95% at usable precision—so reviewers will accept workload reductions without compromising reproducibility. The timing is favorable: advances in LLMs and document-AI materially improve extraction, reproducibility mandates increase demand for auditable workflows, and growth in industry-sponsored reviews raises willingness to pay; market and revenue potential are strong (Market Score 85/100, Revenue Potential 82/100) even with medium competition. To win you must deliver demonstrable end-to-end accuracy, transparent audit trails, validated ROI (time saved per review), and enterprise-grade privacy; expect real challenges from messy PDFs, integration inertia in academic groups, and the need to convert cautious reviewers through independent validations rather than marketing claims.

Market Opportunity

Manual systematic review screening — AI-powered PDF screening and data extraction targets a $3.6B = 600K research teams × $6K ACV (universities, pharma R&D groups, NGOs and clinical review units) total addressable market with medium saturation and a year-over-year growth rate of 15% YoY — driven by growth in AI-assisted research tools and investment in research infrastructure (source: Grand View Research and scholarly publishing market reports, 2023-2024).

Key trends driving demand: Trend — LLMs and document-AI have improved extraction from PDFs, enabling automation of tasks previously done by hand.; Trend — Mandates for reproducibility and structured data in research increase demand for auditable, repeatable review workflows.; Trend — Growth in industry-sponsored systematic reviews (pharma, medtech) increases willingness to pay for time-saving tools.; Trend — Open access and preprint growth increases the volume of literature that needs scalable screening and triage..

Key competitors include Rayyan, Covidence, IRIS.AI, Zotero / Mendeley / Paperpile (reference managers).

Sign in to access

Manual systematic review screening — AI-powered PDF screening and data extraction

Executive Summary

Market Validation

Market Opportunity

More in B2B Software

Small-business grant discovery — centralized database + automated alerts

Streamline dealership ops — centralize inventory, leads, docs & payments

Early-traction trap: convert one-off signups into repeat video-contract users

Manual quoting & installs — AI visual quoting + field workflow automation

Outdated workflows: autonomous AI agents orchestrating ops & data (pain → AI OS)

Map processes first — prevent automating broken manual workflows